Enzyme Multiplied Immunoassay Technique
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
The Enzyme Multiplied Immunoassay Technique, or EMIT, is a common method for screening urine and blood for drugs, whether legal or illicit. It is part of the homogeneous immunoassay.
The technique is relatively nonspecific compared to some other analysis methods, such as mass spectrometry, but has the advantage of being fast and inexpensive. It has, however, been shown in some cases to be somewhat inaccurate in its findings. The patent for EMIT technology is owned by the Syva Corporation of Palo Alto, CA.
In March of 2005, the patent for EMIT technology was sold for an undislosed price to the ORAK Corp, which is based in San Francisco.
See also
External links
- Enzyme+Multiplied+Immunoassay+Technique at the US National Library of Medicine Medical Subject Headings (MeSH)